J Gastroenterology: A long-lasting response to Tovaputan improves the long-term quality of life of cirrhosis.

Background non-compensation cirrhosis combined with stubborn ascites or chest fluid patients had poor prognosis.
tovaputan has been used to treat sodium water storage associated with cirrhosis.
, however, relapses of asymploda have been observed in some cases, despite short-term reactions.
study aims to explore the relationship between relapse rate of ascer abdominal water and long-term recurrence-free response and prognosmation.
method researchers retrospectively analyzed 100 patients with unreponsive cirrhosis treated with tovaptan.
the recurrence rate against the standards of the EASL Clinical Practice Guidelines.
the recurrence rate and prognostication of non-reactive, relapsed patients and long-term responders.
also assessed baseline factors associated with short-term, relapse and long-term reactions, and concluded with statistical analysis.
results showed that about 31.0% of patients with disproparated cirrhosis relapsed after short-term remission.
although there was no significant difference in the prognosmation of short-term reactions (p s 0.07), the prognosmation of long-term responders was significantly better than that of relapses and non-reactive persons (p -lt;0.01).
low CRP levels and high urine Na/K ratio are important factors associated with short-term reactions, while the presence of acute kidney injury is also associated with non-reactive factors.
low CRP level (recurrence: .lt;1.10 mg / dl, long-term response: .lt;0.94 mg / dl) was identified as a factor associated with recurrence and long-term response.
long-term responders who concluded no recurrence had significantly improved prognosmation.
CRP is a useful predictive indicator of long-term reactions, while renal function parameters are a useful predictive indicator of short-term reactions.
control may be important for long-term response and prognosis in patients with cirrhosis.
Masato Nakai. Et al. Reed response without resynation to Tolvaptan improves long-term survival. J Gastroenterology.2020.MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not licensed and may not be reproduced by any media, website or individual, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here.